Blue Horseshoe Stocks

Blue Horseshoe Stocks: Weekly Winners Review

Weekly Winners Review

Yesterday was a great day for so many of the ideas we’ve been discussing this week, leaving our normal routine seemingly unaffected by the holidays. That being said, we’d like to wish all of our readers a prosperous holiday season! 2016 was yet another great year, and we’re already very excited about making 2017 even better!

Micron Technologies, Inc. MU – First up, we’ve got an update on the options idea that we included in yesterday’s premarket report. We signaled the MU Weekly $22-23.50 Calls on the heels of the company’s solid earnings call on Wednesday. All four of the sets of contracts in that range provided big-time gain opportunities:

$22 Calls – Range: .88-1.47 – Max Gain: 67%
$22.50 Calls – Range: .47-1.00 – Max Gain: 113%
$23 Calls – Range: .24-.58 – Max Gain: 142%
$23.50 Calls – Range: .10-.29 – Max Gain: 190%
_____

ERF Wireless, Inc. ERFB – After first alerting ERFB a week ago today, we’ve tracked the stock throughout this week, and witnessed a great run from a low of .0013, to yesterday’s high of .0085. That worked out to an excellent intraweek swing of 554%
_____

Globalstar, Inc. GSAT – Speaking of momentum plays, that’s just what GSAT was when we caught it on Monday morning. It had already strung together four sessions of higher highs, and has managed to maintain that trend for another four! We’ve witnessed an additional increase of 60% from our observed low of 1.25 to yesterday’s new high of 2.00 on heavy volume throughout the week.
_____

Momentous Entertainment Group, Inc. MMEG – We tagged MMEG in Wednesday morning’s premarket report, and that one has made a very nice two-day swing as well. From a low of .0017 to it reached .0038, which represents a 123% spike.
_____

Imprimis Pharmaceuticals, Inc. IMMY – We also just want to remind readers of a signal we gave yesterday morning on IMMY, which had just begun to show signs of a bottom-bounce in the previous session. The stock did continue that trend with a modest 17% move to the upside, trading from a low of 2.12 to 2.48. The jump did occur on well over five times the 3-month average volume, so we’ll continue to observe this play, which has a chance to confirm its multi-day runner status with strong finish to the week.

Extended Watchlist:
ACNV, OTTV, NUVI, AJBI, YIPI, PLX, VNR

Blue Horseshoe Stocks: NKE Review & More

NIKE, Inc. NKE – Options Update

Yesterday we brought a grouping of NKE options ideas to the table following a post-market options beat the previous day.

Despite the slow market conditions that are to be expected of a week leading into the year-end holidays, we felt that NKE was set to provide some opportunities, and we weren’t disappointed.

Our targets for “daytrades and/or swing trades” were the NKE Weekly $52.50-54 Calls and it appears as if both notions will turn out to be correct, with the stock looking like it could post another strong session today. As for the daytrades that were possible yesterday, we saw the most notable moves out of three sets of contracts in our highlighted range:

$52.50 Calls – Range: .15-.38 – Max Gain: 153%
$53 Calls – Range: .07-.21 – Max Gain: 200%
$29 Calls – Range: .03-.09 – Max Gain: 200%

ERF Wireless, Inc. ERFB

We want to provide a quick update on ERFB this morning, which we highlighted in last Friday’s premarket repot. The stock saw a subsequent low of .0013 following that alert, and as of yesterday it had pushed as high as .0079.

That worked out to a 508% intraweek move up, so we want to say congrats to anyone who took this subpenny popper for a ride on the heels of last week’s tag.

Potential Bottom-Plays

We found a pair of stocks this morning that are both trading near their relative bottoms, with strong indications of impending rebounds on both of the charts.

Imprimis Pharmaceuticals, Inc. IMMY
& Ideal Power, Inc. IPWR

In addition to a ripe-looking chart, IMMY has seen some insider buying of late. A recent Form-4 filing revealed a significant buy ($280K) from CEO Mark Baum, who, coincidentally enough, also serves on the board of IPWR. We’re going to keep both of these stocks on recovery watch in the days and weeks ahead.

Fresh Options Idea: MU Weekly $22-23.50 Calls

Extended Watchlist:
INAP, TKAI, RGSE, ANY, HTBX, SYRX

Blue Horseshoe Stocks: CNAT Recap & More

Conatus Pharmaceuticals, Inc. CNAT

We were fairly confident that at least one of the pharma news plays we put forth in yesterday’s premarket report would turn out a promising session, and CNAT definitely rose to the occasion.

We highlighted it, of course, because of a big collaboration and licensing deal for one of the company’s drugs, which adds a quick $50M cash to the books almost immediately, and even more down the road.

After gapping up considerably in the premarket, the stock underwent a dip-and-rip scenario which carried it to a daily low of 4.27 before it pushed its way up to a high of 5.50. That marked a solid intraday upswing of 29% and came on four times the three-month average volume.

ACADIA Pharmaceuticals, Inc. ACAD

ACAD was the other play off of our pharma watchlist that provided us with significant opportunities, which were even bigger than the previously mentioned stock.

We offered an options idea, the ACAD Weekly $28-31 Calls, and all but a couple sets of contracts in that range produced respectable intraday moves.

$28 Calls – Range: .70-1.66 – Max Gain: 137%
$28.50 Calls – Range: .59-1.40 – Max Gain: 137%
$29 Calls – Range: .40-.80 – Max Gain: 100%
$29.50 Calls – Range: .30-.70 – Max Gain: 133%
$30 Calls – Range: .18-.50 – Max Gain: 178%

______

NIKE, Inc. NKE – Fresh Options Idea

NKE is coming off a post-market earnings beat yesterday, so we want to enter an idea into the logs for this situation.

We’re going to be monitoring the activity in the NKE Weekly $52.50-54 Calls for possible daytrades and/or swing trades into the end of the week.

Extended Watchlist:
LEOM, MMEG, INO, ESEA, SINO, DCIX, DRYS, HIMX(Bottom-Watch)

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug. To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: LLY Options Recap & More

Eli Lilly and Co. LLY – Options Update

In our premarket report on Friday morning, we finished off with a set of fresh options ideas for the LLY chain, and were met with nice gain opportunities on the day on all accounts.

In addition to a daytrading idea with the LLY Weekly $72 and $72.50 Calls, which worked out in spades, we also got some really good initial movement out of the longer term target we put forth, the 01/20 $75 Calls.

Weekly $72 Calls – Range: .20-1.25 – Max Gain: 475%
Weekly $72.50 Calls – Range: .15-.80 – Max Gain: 433%
1/20 $75 Calls – Range: .77-1.39 – Max Gain: 81%

We offer congratulations to anyone who benefited from the short-term ideas, and we’ll be sure to stay on the trail of those 01/20 $75 Calls in the weeks ahead.

Globalstar, Inc. GSAT

We caught a glimpse of GSAT on our scanner this morning and feel it’s worthy of mentioning, based on a number of factors. Last week, the moves that the stock had been making off of its recent relative lows in the low .70-range began to increase.

On Thursday, the stock bullishly breached its 50DMA, culminating in a huge spike in volume on Friday. Roughly six times the monthly average trading volume accompanied a break of the dollar mark. We’re going to put this on watch as a possible momentum play.

AmpliPhi BioSciences, Inc. APHB

Speaking of bottom-bouncers, APHB cropped on our scan as well, and it has a look of high potential as it’s coming up off of its recently established annual lows.

In addition, there’s a gap to fill on the chart to the upside, and with the stock already trading up in the premarket, that’s a real possibility here. With such a ripe chart, we’ll be very interested to follow APHB’s activity out of the gate this morning.

Extended Watchlist:
NHMD, ECPN, EVOK, APTO, ANY(Bottom Play)